PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IGG DEPOSITS

Clinical trials for PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IGG DEPOSITS explained in plain language.

Never miss a new study

Get alerted when new PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IGG DEPOSITS trials appear

Sign up with your email to follow new studies for PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IGG DEPOSITS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New shot tested for rare, devastating kidney disease

Disease control Recruiting now

This study is testing if a drug called daratumumab, given as an injection, can help people with a rare kidney disease called PGNMID. The main goal is to see if the treatment can reduce the amount of protein leaking into the urine and improve kidney function over 12 months. Resear…

Matched conditions: PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IGG DEPOSITS

Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IGG DEPOSITS

Get alerted when new PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IGG DEPOSITS trials appear

New shot tested for rare, devastating kidney disease